Subcutaneous Trastuzumab (Herceptin<sup>®</sup>): A UK Time and Motion Study in Comparison with Intravenous Formulation for the Treatment of Patients with HER2-Positive Early Breast Cancer
Advances in Breast Cancer Research · 2013 · 02 (04) · 133-140
DOI: 10.4236/abcr.2013.24022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Breast Cancer Research, 2013. Verfasst von Russell Burcombe und 5 weiteren Autor:innen. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Burcombe, R., Chan, S., Simcock, R., Samanta, K., Percival, F., & Barrett-Lee, P. (2013). Subcutaneous Trastuzumab (Herceptin®): A UK Time and Motion Study in Comparison with Intravenous Formulation for the Treatment of Patients with HER2-Positive Early Breast Cancer. Advances in Breast Cancer Research, 02(04), 133-140. https://doi.org/10.4236/abcr.2013.24022
Vancouver
Burcombe R, Chan S, Simcock R, Samanta K, Percival F, Barrett-Lee P. Subcutaneous Trastuzumab (Herceptin®): A UK Time and Motion Study in Comparison with Intravenous Formulation for the Treatment of Patients with HER2-Positive Early Breast Cancer. Advances in Breast Cancer Research. 2013;02(04):133-140. doi:10.4236/abcr.2013.24022
BibTeX
@article{Burcombe2013,
author = {Burcombe, Russell and Chan, Steve and Simcock, Richard and Samanta, Kunal and Percival, Fran and Barrett-Lee, Peter},
title = {Subcutaneous Trastuzumab (Herceptin®): A UK Time and Motion Study in Comparison with Intravenous Formulation for the Treatment of Patients with HER2-Positive Early Breast Cancer},
journal = {Advances in Breast Cancer Research},
year = {2013},
volume = {02},
number = {04},
pages = {133--140},
doi = {10.4236/abcr.2013.24022}
}
EUVIMED